Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints
暂无分享,去创建一个
Wiesje M. van der Flier | Philip Scheltens | Pieter Jelle Visser | Charlotte E. Teunissen | P. Scheltens | P. Visser | Y. Pijnenburg | W. Flier | M. Blankenstein | C. Teunissen | Argonde C. van Harten | Yolande A.L. Pijnenburg | Marinus A. Blankenstein | A. V. Harten
[1] J. Gunter,et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.
[2] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[3] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[4] Todd E. Golde,et al. Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.
[5] John X. Morris,et al. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease , 2011, Neurology.
[6] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[7] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[8] A. Wallin,et al. Cognitive Profiles of Incipient Dementia in the Goteborg MCI Study , 2010, Dementia and Geriatric Cognitive Disorders.
[9] M. Blankenstein,et al. Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β (1-42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop , 2010, International journal of Alzheimer's disease.
[10] F. Jessen,et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. , 2010, Archives of general psychiatry.
[11] D. Brooks,et al. 11C-PIB PET in subjective cognitive impairment , 2010, European Psychiatry.
[12] W. M. van der Flier,et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. , 2010, Clinical chemistry.
[13] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[14] P. Visser,et al. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. , 2010, Journal of Alzheimer's disease : JAD.
[15] Oscar L. Lopez,et al. Telephone Interview for Cognitive Status , 2009, Neuroepidemiology.
[16] A. Fagan,et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.
[17] W. M. van der Flier,et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease , 2009, Neurology.
[18] John Hardy,et al. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal , 2009, Journal of neurochemistry.
[19] C. Jack,et al. MRI and CSF biomarkers in normal, MCI, and AD subjects , 2009, Neurology.
[20] W. M. van der Flier,et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.
[21] Magda Tsolaki,et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.
[22] A. Mitchell,et al. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies , 2009, Journal of Neurology, Neurosurgery & Psychiatry.
[23] H. Braak,et al. Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship , 2009, Journal of neuropathology and experimental neurology.
[24] W. M. van der Flier,et al. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. , 2009, Journal of Alzheimer's disease : JAD.
[25] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[26] O. Forlenza,et al. Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[27] K. Blennow,et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI , 2007, Neurology.
[28] Paul Maruff,et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .
[29] I. Sokal,et al. CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.
[30] K. Blennow,et al. Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly , 2007, Dementia and Geriatric Cognitive Disorders.
[31] A. Fagan,et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.
[32] S. Bouwens,et al. Telefonisch Interview Cognitieve Status (TICS): psychometrische aspecten , 2007 .
[33] K. Blennow,et al. Cerebrospinal fluid β-amyloid 1–42 concentration may predict cognitive decline in older women , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[34] F. Verhey,et al. [The psychometric properties of the Dutch version of the Telephone Interview Cognitive Status (TICS)]. , 2007, Tijdschrift voor gerontologie en geriatrie.
[35] G. Schellenberg,et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. , 2007, Neurology.
[36] Paul Maruff,et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.
[37] E. Tangalos,et al. Neuropathologic features of amnestic mild cognitive impairment. , 2006, Archives of neurology.
[38] K. Blennow,et al. CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.
[39] A Drzezga,et al. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. , 2002, Archives of neurology.
[40] P. Deyn,et al. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.
[41] L. Bouter,et al. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. , 1999, The American journal of psychiatry.
[42] E. Tangalos,et al. Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .
[43] J. Price,et al. Cerebral amyloid deposition and diffuse plaques in ``normal'' aging , 1996, Neurology.
[44] H. Chui,et al. Multicenter clinicopathological correlation in dementia. , 1995, The American journal of psychiatry.
[45] J. Hardy,et al. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.
[46] Vijaya L. Melnick,et al. Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.
[47] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.